AAPL343.37+3.29 (+0.97%) ▲|ABBV265.81+2.61 (+0.99%) ▲|ABT108.74+1.47 (+1.37%) ▲|ACN174.95+10.29 (+6.25%) ▲|ADBE264.54+15.36 (+6.16%) ▲|AMAT450.72-25.74 (-5.40%) ▼|AMD438.41-16.21 (-3.57%) ▼|AMGN389.84-3.26 (-0.83%) ▼|AMT173.52+2.02 (+1.18%) ▲|AMZN231.30+0.44 (+0.19%) ▲|AVGO377.12-3.80 (-1.00%) ▼|AXP333.13-3.51 (-1.04%) ▼|BA215.89-5.68 (-2.56%) ▼|BAC61.60-1.03 (-1.64%) ▼|BKNG204.03+4.72 (+2.37%) ▲|BLK1,098.17+0.62 (+0.06%) ▲|BMY63.67+0.07 (+0.10%) ▲|BNY153.55-2.95 (-1.88%) ▼|BRK-B510.63-1.75 (-0.34%) ▼|C127.65-4.83 (-3.64%) ▼|CAT781.26-59.60 (-7.09%) ▼|CL93.31+0.58 (+0.62%) ▲|CMCSA24.85+0.66 (+2.71%) ▲|COF210.38-2.03 (-0.96%) ▼|COP118.22+4.12 (+3.61%) ▲|COST974.80+8.22 (+0.85%) ▲|CRM189.06+7.56 (+4.17%) ▲|CSCO114.03-1.56 (-1.35%) ▼|CVS106.54-2.80 (-2.56%) ▼|CVX191.72+4.14 (+2.21%) ▲|DE614.72-25.13 (-3.93%) ▼|DHR198.11-0.94 (-0.47%) ▼|DIS98.89+0.00 (+0.00%) ▲|DUK129.38+0.14 (+0.11%) ▲|EMR146.87-4.94 (-3.25%) ▼|FDX309.34-3.31 (-1.06%) ▼|GD388.52-4.67 (-1.19%) ▼|GE353.79-9.80 (-2.70%) ▼|GEV906.96-36.42 (-3.86%) ▼|GILD134.43+0.11 (+0.08%) ▲|GM91.16+0.86 (+0.95%) ▲|GOOG338.98+6.38 (+1.92%) ▲|GOOGL339.83+6.12 (+1.83%) ▲|GS991.09-42.25 (-4.09%) ▼|HD340.69-3.78 (-1.10%) ▼|HON243.80-3.26 (-1.32%) ▼|IBM228.83+1.28 (+0.56%) ▲|INTC83.98-2.32 (-2.69%) ▼|INTU335.65+22.66 (+7.24%) ▲|ISRG354.36-7.44 (-2.06%) ▼|JNJ266.31-0.42 (-0.16%) ▼|JPM347.40-9.92 (-2.77%) ▼|KO89.12+0.85 (+0.96%) ▲|LIN511.51+0.33 (+0.06%) ▲|LLY1,218.56-2.11 (-0.17%) ▼|LMT576.19-5.12 (-0.88%) ▼|LOW217.71-0.53 (-0.24%) ▼|LRCX258.45-11.16 (-4.14%) ▼|MA566.34+3.59 (+0.64%) ▲|MCD272.04-0.99 (-0.36%) ▼|MDLZ65.20+2.72 (+4.35%) ▲|MDT87.62+0.74 (+0.85%) ▲|META593.40-0.02 (0.00%) ▼|MMM179.43-3.05 (-1.67%) ▼|MO75.17+0.35 (+0.47%) ▲|MRK131.08-0.74 (-0.56%) ▼|MS204.67-6.91 (-3.27%) ▼|MSFT398.10+4.75 (+1.21%) ▲|MU763.76-56.78 (-6.92%) ▼|NEE88.83-0.45 (-0.50%) ▼|NFLX73.58+1.19 (+1.64%) ▲|NKE43.17+0.12 (+0.27%) ▲|NOW116.38+5.76 (+5.21%) ▲|NVDA192.84-4.17 (-2.12%) ▼|ORCL119.28-0.69 (-0.57%) ▼|PEP144.34+1.48 (+1.04%) ▲|PFE25.20-0.06 (-0.22%) ▼|PG145.07-3.82 (-2.56%) ▼|PLTR125.19+1.66 (+1.34%) ▲|PM199.72-0.46 (-0.23%) ▼|QCOM160.70-2.19 (-1.34%) ▼|RTX218.92+0.34 (+0.16%) ▲|SBUX104.02+0.92 (+0.89%) ▲|SCHW105.62-0.35 (-0.33%) ▼|SO96.21-0.57 (-0.59%) ▼|SPG237.38+0.68 (+0.29%) ▲|T24.33-0.34 (-1.36%) ▼|TMO571.53-4.88 (-0.85%) ▼|TMUS182.00-0.39 (-0.21%) ▼|TSLA302.43-5.01 (-1.63%) ▼|TXN275.59-1.49 (-0.54%) ▼|UBER71.36+0.62 (+0.88%) ▲|UNH421.63-7.16 (-1.67%) ▼|UNP291.27-3.18 (-1.08%) ▼|UPS104.26-1.28 (-1.21%) ▼|USB63.17-1.26 (-1.96%) ▼|V368.81+2.22 (+0.61%) ▲|VZ48.40+0.21 (+0.43%) ▲|WFC84.44-2.43 (-2.80%) ▼|WMT114.08+0.98 (+0.87%) ▲|XOM156.55+3.51 (+2.29%) ▲|AAPL343.37+3.29 (+0.97%) ▲|ABBV265.81+2.61 (+0.99%) ▲|ABT108.74+1.47 (+1.37%) ▲|ACN174.95+10.29 (+6.25%) ▲|ADBE264.54+15.36 (+6.16%) ▲|AMAT450.72-25.74 (-5.40%) ▼|AMD438.41-16.21 (-3.57%) ▼|AMGN389.84-3.26 (-0.83%) ▼|AMT173.52+2.02 (+1.18%) ▲|AMZN231.30+0.44 (+0.19%) ▲|AVGO377.12-3.80 (-1.00%) ▼|AXP333.13-3.51 (-1.04%) ▼|BA215.89-5.68 (-2.56%) ▼|BAC61.60-1.03 (-1.64%) ▼|BKNG204.03+4.72 (+2.37%) ▲|BLK1,098.17+0.62 (+0.06%) ▲|BMY63.67+0.07 (+0.10%) ▲|BNY153.55-2.95 (-1.88%) ▼|BRK-B510.63-1.75 (-0.34%) ▼|C127.65-4.83 (-3.64%) ▼|CAT781.26-59.60 (-7.09%) ▼|CL93.31+0.58 (+0.62%) ▲|CMCSA24.85+0.66 (+2.71%) ▲|COF210.38-2.03 (-0.96%) ▼|COP118.22+4.12 (+3.61%) ▲|COST974.80+8.22 (+0.85%) ▲|CRM189.06+7.56 (+4.17%) ▲|CSCO114.03-1.56 (-1.35%) ▼|CVS106.54-2.80 (-2.56%) ▼|CVX191.72+4.14 (+2.21%) ▲|DE614.72-25.13 (-3.93%) ▼|DHR198.11-0.94 (-0.47%) ▼|DIS98.89+0.00 (+0.00%) ▲|DUK129.38+0.14 (+0.11%) ▲|EMR146.87-4.94 (-3.25%) ▼|FDX309.34-3.31 (-1.06%) ▼|GD388.52-4.67 (-1.19%) ▼|GE353.79-9.80 (-2.70%) ▼|GEV906.96-36.42 (-3.86%) ▼|GILD134.43+0.11 (+0.08%) ▲|GM91.16+0.86 (+0.95%) ▲|GOOG338.98+6.38 (+1.92%) ▲|GOOGL339.83+6.12 (+1.83%) ▲|GS991.09-42.25 (-4.09%) ▼|HD340.69-3.78 (-1.10%) ▼|HON243.80-3.26 (-1.32%) ▼|IBM228.83+1.28 (+0.56%) ▲|INTC83.98-2.32 (-2.69%) ▼|INTU335.65+22.66 (+7.24%) ▲|ISRG354.36-7.44 (-2.06%) ▼|JNJ266.31-0.42 (-0.16%) ▼|JPM347.40-9.92 (-2.77%) ▼|KO89.12+0.85 (+0.96%) ▲|LIN511.51+0.33 (+0.06%) ▲|LLY1,218.56-2.11 (-0.17%) ▼|LMT576.19-5.12 (-0.88%) ▼|LOW217.71-0.53 (-0.24%) ▼|LRCX258.45-11.16 (-4.14%) ▼|MA566.34+3.59 (+0.64%) ▲|MCD272.04-0.99 (-0.36%) ▼|MDLZ65.20+2.72 (+4.35%) ▲|MDT87.62+0.74 (+0.85%) ▲|META593.40-0.02 (0.00%) ▼|MMM179.43-3.05 (-1.67%) ▼|MO75.17+0.35 (+0.47%) ▲|MRK131.08-0.74 (-0.56%) ▼|MS204.67-6.91 (-3.27%) ▼|MSFT398.10+4.75 (+1.21%) ▲|MU763.76-56.78 (-6.92%) ▼|NEE88.83-0.45 (-0.50%) ▼|NFLX73.58+1.19 (+1.64%) ▲|NKE43.17+0.12 (+0.27%) ▲|NOW116.38+5.76 (+5.21%) ▲|NVDA192.84-4.17 (-2.12%) ▼|ORCL119.28-0.69 (-0.57%) ▼|PEP144.34+1.48 (+1.04%) ▲|PFE25.20-0.06 (-0.22%) ▼|PG145.07-3.82 (-2.56%) ▼|PLTR125.19+1.66 (+1.34%) ▲|PM199.72-0.46 (-0.23%) ▼|QCOM160.70-2.19 (-1.34%) ▼|RTX218.92+0.34 (+0.16%) ▲|SBUX104.02+0.92 (+0.89%) ▲|SCHW105.62-0.35 (-0.33%) ▼|SO96.21-0.57 (-0.59%) ▼|SPG237.38+0.68 (+0.29%) ▲|T24.33-0.34 (-1.36%) ▼|TMO571.53-4.88 (-0.85%) ▼|TMUS182.00-0.39 (-0.21%) ▼|TSLA302.43-5.01 (-1.63%) ▼|TXN275.59-1.49 (-0.54%) ▼|UBER71.36+0.62 (+0.88%) ▲|UNH421.63-7.16 (-1.67%) ▼|UNP291.27-3.18 (-1.08%) ▼|UPS104.26-1.28 (-1.21%) ▼|USB63.17-1.26 (-1.96%) ▼|V368.81+2.22 (+0.61%) ▲|VZ48.40+0.21 (+0.43%) ▲|WFC84.44-2.43 (-2.80%) ▼|WMT114.08+0.98 (+0.87%) ▲|XOM156.55+3.51 (+2.29%) ▲|
26.8 C
New York
Wednesday, July 29, 2026

Tag: infections

newssourceFORcompanyinformationcontent1releasesmarket

Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb

New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.

20 Years of Lyme Disease Advocacy Fuels New Chapter for Tick BYTES

Founders Offer Do It Yourself Tick Control Tools and Resources WINDHAM, Maine, July 30, 2025 /PRNewswire/ -- Barb and Bob Maurais have launched Tick BYTES (Back Yard...

Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections

Allschwil, Switzerland, July 29, 2025

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

Full Alliance Group Reports Second Quarter Preliminary results, Unveils Expansion into High-Growth Men’s Wellness Personal Care and Health Virility segment, Association Digital Benefits, and...

Full Alliance Group (OTC:FAGI) shows ~50% y-o-y unaudited revenue increase for Q2 2025 and provides exciting outlook, driven by strategic expansion

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.

Local Plastic Surgeon in Paramus New Jersey, Dr. Andrew Nouri Educates Patients on Insurance Coverage for Medically Necessary Breast Reduction

Paramus, NJ, July 23, 2025 (GLOBE NEWSWIRE) -- For many women, large breasts are not just a cosmetic concern, they’re a medical one. Chronic back, neck, and shoulder pain, rashes under the breasts, painful grooves from bra straps, posture problems, and even emotional distress are just some of the symptoms that can come with disproportionately large breasts.

XORTX Completes Non-Brokered Private Placement of Units

Not For Distribution to United States News Wire Services or for Dissemination in the United States

Llusern Scientific Announces Key Appointments to Strengthen its Executive Team

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide 
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfections

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers